Evidence map›Paper›PMID 34427047›Full record

Trial reportEarly intervention in psychiatry2022

Family-focused therapy for individuals at high clinical risk for psychosis: A confirmatory efficacy trial.

David J Miklowitz, Jean M Addington, Mary P O'Brien, Danielle M Denenny, Marc J Weintraub, Jamie L Zinberg, Daniel H Mathalon, Barbara A Cornblatt, Michelle S Friedman-Yakoobian, William S Stone and 5 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Early intervention in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

David J MiklowitzDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuropsychiatry and Behavior, University of California, Los Angeles, California, USA.ORCID 0000-0002-9647-6147
Jean M AddingtonDepartment of Psychiatry, University of Calgary, Calgary, Canada.ORCID 0000-0002-8298-0756
Mary P O'BrienDepartment of Psychology, Yale University, New Haven, Connecticut, USA.
Danielle M DenennyDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuropsychiatry and Behavior, University of California, Los Angeles, California, USA.
Marc J WeintraubDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuropsychiatry and Behavior, University of California, Los Angeles, California, USA.ORCID 0000-0001-8724-120X
Jamie L ZinbergDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuropsychiatry and Behavior, University of California, Los Angeles, California, USA.
Daniel H MathalonDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
Barbara A CornblattDivision of Psychiatry Research, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA.
Michelle S Friedman-YakoobianDepartment of Public Psychiatry Massachusetts Mental Health Center, Harvard Medical School at Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
William S StoneDepartment of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Kristin S CadenheadDepartment of Psychiatry, University of California, San Diego, La Jolla, California, USA.
Scott W WoodsDepartment of Psychiatry, Yale University, New Haven, Connecticut, USA.
Catherine A SugarDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuropsychiatry and Behavior, University of California, Los Angeles, California, USA.
Tyrone D CannonDepartment of Psychology, Yale University, New Haven, Connecticut, USA.
Carrie E BeardenDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuropsychiatry and Behavior, University of California, Los Angeles, California, USA.
University of California, Los Angeles · USYale University · USBeth Israel Deaconess Medical Center · USNorthwell Health · USUniversity of Calgary · CAUniversity of California San Diego · USUniversity of California, San Francisco · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy TrialR01MH123575 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E, MIKLOWITZ, DAVID JAY · 2020 to 2023
$5.4M
Neurodevelopment and Psychosis in the 22q11.2 Copy Number VariantsR37MH085953 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CARRIE E BEARDEN · 2023 to 2026
$2.9M
NCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH123575NIMH NIH HHS R37 MH085953
6 · The paper itself

Abstract

aimsYoung people with attenuated psychotic symptoms (APS), brief intermittent psychosis, and/or genetic risk and functional deterioration are at high risk for developing psychotic disorders. In a prior trial, family-focused therapy for clinical high risk youth (FFT-CHR) was more effective than brief psychoeducation in reducing APS severity over 6 months. This 7-site trial will compare the efficacy of FFT-CHR to a psychoeducational and supportive intervention (enhanced care) on APS and social functioning in CHR individuals over 18 months.

methodsParticipants (N = 220, ages 13-25 years) with a CHR syndrome will be randomly assigned to FFT-CHR (18 1-h sessions of family psychoeducation and communication/problem-solving skills training) or enhanced care (3 1-h family psychoeducational sessions followed by 5 individual support sessions), both given over 6 months. Participants will rate their weekly progress during treatment using a mobile-enhanced online platform. Family communication will be assessed in a laboratory interactional task at baseline and post-treatment. Independent evaluators will assess APS (primary outcome) and psychosocial functioning (secondary outcome) every 6 months over 18 months.

resultsWe hypothesize that, compared to enhanced care, FFT-CHR will be associated with greater improvements in APS and psychosocial functioning over 18 months. Secondarily, improvements in family communication over 6 months will mediate the relationship between treatment condition and primary and secondary outcomes over 18 months. The effects of FFT-CHR are predicted to be greater in individuals with higher baseline risk for psychosis conversion.

conclusionsResults of the trial will inform treatment guidelines for individuals at high risk for psychosis.

Indexed as

Family TherapyPsychotic DisordersAdolescentAdultCommunicationHumansSocial AdjustmentYoung Adultexpressed emotionfamily therapyprodromal symptomspsychotic disorderssocial adjustment

Identifiers

PMID34427047
PMCPMC8863959
OpenAlexW3194865866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.